Prof. Xinxiang Li 李心翔
Chief Physician, Professor
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive laparoscopic surgery for colorectal cancer, including ultra-low sphincter-preserving rectal cancer resection and colectomy. Focuses on comprehensive surgical care for elderly patients and those with liver or lung metastases or postoperative recurrence.
Dr. Li is a Professor and Chief Physician at Fudan University Shanghai Cancer Center. Dr. Li conducted clinical work and research at the Cleveland Clinic Florida Minimally Invasive Surgery Center. After returning to China, Dr. Li pioneered various laparoscopic colorectal procedures, including the first international case of laparoscopic transanal pull-through non-angled double stapling technique.
Professional roles
- Chair, Gastrointestinal Tumor Laparoscopy Professional Committee, Shanghai Anti-Cancer Association
- Vice Chair, Colorectal Tumor Laparoscopy Professional Committee, Chinese Medical Doctor Association
- Standing Committee Member, Anorectal Physicians Branch, Chinese Medical Doctor Association
- International Member, Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
Name order: in Chinese the family name comes first (Li Xinxiang). Papers usually list the name as Xinxiang Li or Li X.
Selected publications
166 papers on PubMed matched by name and affiliation; 57 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Invest Surg, 2026 (senior author): Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in a Chinese High-Volume Cancer Center. PubMed 42300690
- Clin Exp Pharmacol Physiol, 2026 (first author): Context-Dependent Associations of GCN1 With Malignant Phenotypes, Immune-Related Features and Prognosis in Colorectal Cancer. PubMed 43000220
- Acta Biochim Biophys Sin (Shanghai), 2026 (senior author): E3 ubiquitin ligase COP1-mediated GSK3β degradation activates β-catenin signaling to facilitate colorectal cancer cell proliferation. PubMed 42057424
- J Gastrointest Oncol, 2026 (senior author): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer. PubMed 42169920
- Exp Hematol Oncol, 2026 (senior author): Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation. PubMed 41937206
- Clin Transl Med, 2026 (senior author): PVT1-104aa derived from the 8q24 gene desert promotes colorectal cancer tumorigenesis. PubMed 41952439
- Oncologist, 2026 (senior author): Long-term outcomes following a pathological complete response at the primary tumor site after preoperative therapy in metastatic colorectal cancer. PubMed 41630525
- Clin Cancer Res, 2025 (senior author): Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study. PubMed 41026606
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion